Oric Pharmaceuticals Inc. (NASDAQ:ORIC)

Chart of the Day June 7th, 2021

View Entire Video (27:34)
Chart of the Day
June 7th, 2021
   00:00
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
ORIC Weekly Chart

Old Forum Content for ORIC

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $ORIC on a continuing climb.
  • woodman: $ORIC another biotech that's doing well. I let this one go at theAug/ Sept. highs. Tough decisions meant I had to choose which to stay in and which to let go or not buy back. I chose to stick with others and never got back in to Oric, but it sure has been nice since bottoming in Oct. It's up over 175% since that bottom.
  • woodman: $ORIC up off the 50d through the 8dEMA. But low volume.
  • woodman: $ORIC - I'm a soldout bull for this one. Sadly, there was no more room in my biotech portfolio. Something had to give and this is what went.
  • woodman: $ORIC - lots of confidence shown here by its private placement of ~12.5 mil shares to select investors. Data coming in Q2 and Q3, I believe. I've lost track. I made the tough choice of letting this one go (in legs in June, Aug and Sep)t. There was too much competiton for my biotech dollars, so I let it go to concentrate the $$ in other biotechs. Bummer.
  • heyjack: $ORIC new 2 year high but has a ways to go to get to a 3 year high
  • woodman: $ORIC strong bounce off the 50d. Still needs to get up through some resistance around $9.50 or so. I have to check on next catalysts/data. This one has gotten away from me. I let this go a while back, and since then I've had to make hard choices on where to put my biotech dollars. Happy with what I am doing, but I do need to look at this one again.
  • heyjack: $ORIC Spent a few days at the 50 day but made a nice bounce today. Volume nothing to get excited about.
  • woodman: #Biotechs I'm focusing on (mostly for at least Q1/H1 2024) (in no particular order): $ARDX (I plan to contnue holding this through full year 2024) $EFTR $XFOR $VKTX $MREO (good buyout potential) $PDSB $INZY $CLRB (mainly for 1/8 data to be presented at JPM Healthcare Conf). Possibly some others as well such as $ORIC (I've lost focus on it and need to reacquaint myself) and $ACAD.
  • woodman: $ORIC another recent new high.
  • woodman: $ORIC marching higher
  • woodman: $ORIC back on the rise into catalysts in December and January. I have a pre-existing small position to which I may add. Unfortunately, I lost sight of this one a little bit. The potentially value-creating near term catalysts include ORIC-533 in multiple myeloma (phase 1b confirmed ASH) and ORIC-944 in prostate cancer (phase 1b JPM's guess is ASCO GU in January).
  • woodman: @Lou $INZY - Nice one. Many of the small biotechs are showing life. $XBI has moved above descending resistance (drawn from 6/12). See, e.g., $PDSB which has been hot. It is trying to hold its latest move up through the 200d (it easily moved up through the descending 50d a week and a half ago). $ORIC and $VKTX are holding their moves through the descending 50d so far. Another interesting one is $MREO which is high consolidation right now.
  • MongosPawn: @woodman $INZY Me too. However, I did have to pull the plug on $ORIC when it didn't hold at the 100 dma. Lost some on the recent buys. But overall, made some very good dough along the way due to your guidance from last spring. Thanks!
  • woodman: @MongosPawn $INZY $ORIC - I pulled the plug on ORIC in my two accounts that had it on 8/28 and 9/14, respectively. My decisions were a combo of the chart and my desire for things I wanted more as I consolidated my biotech holdings. I'm down to very few biotechs, though I have some on the horizon that I used to own (i.e. want to buy back). My primary biotech holdings currently are $ARDX (large position), $INZY and $NWBiOturd ($NWBO - a lottery ticket stock that I've held for some time, which I seem recently to have caught nicely in the $0.40s & $0.50s to add to my shares that I bought higher). $PDSB remains interesting and has a bunch of catalysts coming this week and next! I am looking possibly to buy back some of those shares. I also will buy back $XFOR for catalysts in December.
  • MongosPawn: $ARDX $ORIC Added small.
  • MongosPawn: $ORIC Added small on the bounce today.
  • MongosPawn: $ORIC Some nice after hours action last night.
  • woodman: $ARDX $XFOR $INZY $ORIC $PDSB - My biotechs are working well today but, alas, they are all still in a range, though ORIC may be poised to move up out of its range (we'll see).
  • woodman: $ORIC has been holding up well as it continues to consolidate on relatively low volume. Over the last week and a half, it has been banging away at the top of this nearly 2-month consolidation with the 50 day continuing to rise and now firmly within t ...
  • woodman: $ORIC - Moving well out of consolidation, up through $9 resistance. Lots going on with ORIC. I think its moving today on Baird's increased PT from $15 to $27, which is probably based on news regarding $PFE (a collaborator with ORIC). Recall that $PF ...
  • jwstich: @woodman $ORIC $PFE $JNJ Thank you for your well done update. Been adding to this poition over the last few months. I really appreciate what you add to the forum and always raed your posts.
  • woodman: @jwstich $ORIC $PFE $JNJ - Thank you. Much appreciated.
  • woodman: $ORIC - nice consolidation above/into the 50d. ~$9 is the resistance area.
  • MongosPawn: @woodman $XFOR Love the long term potential. No worries on the DD. Couldn't agree more. I've done or am doing pretty well with many of the suggestions that you've brought to our attention ($ARDX, $ORIC, $IONQ to name a few). You get much of the credit with the winners, I get all of the blame with any losers. Again, no worries. Thanks!
  • woodman: $ORIC putting in some green at bottom of current range. I could see it climb back to top of the range around ~9. A move up and out of the range would provides lots of room for a move higher. Catalysts this half of the year, but I don't have specific dates.
  • woodman: @wijimmy $NANC $KRUZ $QQQ $EFTR - I don't have any more intel on EFTR. I need to look into it. My position remains small. It has two catalysts due this half of the year, but I don't know when. Some others have been of greater immediate interest to me with coming catalysts: $XFOR (I'm very interested - and have a healthy position - in this one with its much anticipated CN data coming this month or next, I'm guessing) and $INZY (one on Wednesday then next Q). $ORIC seems to be making a run into catalysts this half of the year, but I don't have a specific month even. Others of interest include these struggling ones: $TERN (catalysts this Q and another this H), $VKTX (two catalysts this H). $PDSB (one this H).
  • woodman: $ORIC holding up well - finding support at 8dEMA as it consolidates again after a strong move out of a base from late April to early/mid June. Three cancer related data readouts this half of the year (I don't have a more precise date, currently).
  • woodman: @Lou $PDSB - for got $ORIC, another one I have and want to build on for catalysts this half. Probably won't be able to build them all to the levels I'd like.
  • woodman: $ORIC - good action within flag consolidation at the 8dEMA after big move up on 6/26-6/27 and pullback of about half that move.
  • woodman: $ORIC holding up well with a doji today after yesterday's strong move. I'm still in this. Remember that $PFE is partnered with ORIC (in ORIC-533 - which has data coming in 2H this year - anti-tumor activity from ongoing single agent Ph1b study in patients with multiple myeloma) and bought a bunch of ORIC stock at $4.65/share in December. PFE saw early data in the trial they partnered with. Its CSO for oncology and R&D joined $ORIC scientific advisory board. It knew what it was buying. There also was a private placement for big healthcare funds at a premium; participating investors entered into confidentiality agreements and executed lock-up agreements with ORIC to restrict their ability to sell ORIC shares. Lots of confidence here from big money. Riding the coattails.
  • geothrills: Sold a quarter of my $ORIC. Although the upside targets on this one are generally somewhere around $15, which is roughly another double, it is prudent to habitually trim positions when they move very far very fast. ORIC's 30% move yesterday alone (on the heels of an $85 million capital infusion into the company, which indicates institutional sponsorship), qualifies for some prudent profit taking. I won't be too quick to sell all of it, as I want to wait for their three preliminary clinical study results on their cancer treatments, two of which are due before the year is out, and the third of which is expected in 2024. But I also, out of discipline, want to rebalance the position, as it has grown to become a considerably larger portion of my portfolio than when I first initiated it. Thanks again @woodman for drawing attention to this one.
  • MongosPawn: $ORIC On the move.
  • woodman: $ORIC @MongosPawn - fyi. https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-announces-85-million-private-placement
  • MongosPawn: @woodman $ORIC Thanks. Saw that news but am not sure why that makes the stock soar way past the agreed to offering price. Me = Neophyte.
  • woodman: $ORIC gunning for recent high of 6.85. $TERN continues its move off rising support. Potential Russell 3000 additions boost around the corner. (These topics and others discussed on 6/20.)
  • woodman: ...
    Additionally, TERN is one of the bios I'm holding over their additions into the Russell 3000 on Fri 6/23 amc (for trading in the index on Mon 6/26). Funds will have to buy it. In addition to TERN, I have several other biotechs that will be added to ...
  • woodman: @MongosPawn $ARDX $XFOR - It was a rough day for almost all of my bios today. (Sigh.) There are a number I'd like to add to, but I don't have available cash for them all. I sold some $ORIC today because it looked toppy. I need a more precise idea of when ORIC's catalysts are - I know H2, that's about it.
  • MongosPawn: $ORIC Added small.
  • woodman: $ORIC moving up through descending resistance drawn from 1/23 this year. Long.
  • geothrills: Thanks @woodman Credit where credit's due. Not my typical trade, but I wanted to park some capital in something "less exciting" and your analysis regarding the impending potential catalysts on $ORIC in conjunction with the squeeze that it was in, had me build a modest position between $5.05-$5.15, before the recent volume spikes. As Dan noted, it is a bit thin, but I liked how clear support was and figured upside to downside was somewhere around three to one, which is worth a shot in my book.
  • woodman: @geothrills $ORIC - I was unaware Dan mentioned it. I do agree with you and Dan that it's a bit thin. I generally haven't let that stop me with the biotechs in which I've become interested and decided to buy. I have a decent position in this one starting from the mid-4s off the 200d in March with adds up through the mid 5s and recently to a lesser degree here with a 6 handle.
  • woodman: $ORIC good action in this one lately, though stymied by descending resistance / wedge top drawn from 1/23. I continue to stay invested in this one. Three data readouts this H covering various cancer types (prostate; solid tumors/advanced malignancies; multiple myeloma). PTs are 14-16; currently trading at 5.50.
  • Dale: $ORIC what's the news causing the jump?
  • woodman: @Dale $ORIC - Not sure. I've been holding this, and adding here and there, Nice to finally see it break through 5.50 again. It has 3 catalysts H2 this year.
  • MongosPawn: $ORIC Opened with a gap above all of the dma's. Let's see if it can close above them. After all, it's not how you start. It's how you finish that counts.
  • woodman: @MongosPawn $ORIC - I'm still a faithful holder of this. Testing 5.50 resistance. Price targets are much higher - about 3x (ranging from 14 to 16). Catalysts in H2 for multiple forms of cancer/malignancies.
  • woodman: $ORIC - Worth keeping an eye on. It's looking lively today. It's a thinly trading cancer biotech within a squeeze at the 50d. It's been consolidating after a pullback. It has 3 catalysts in the second half of the year. Price targets are 3x higher.
  • woodman: $ORIC grinding along the 50d in consolidation. I *think* this will resolve to the upside ultimately to test April highs. That's partially my gut speaking based on the chart, plus coming catalysts in H2 of this year with price targets that are 3x higher than current price.
  • woodman: $ORIC - making higher daily highs since pulling back to the 50d/under $5 last week.
  • woodman: $ORIC continues to firm up at support (50d & rising support)
  • woodman: $ORIC, which has a nice run since March is pulling back and now testing rising support (from last Nov.) and the 50d (and occuring at the bottom BB). Technically, the recent lower high (4/17 vs 1/23) is somewhat of a concern, but can also be viewed as ...
  • steve71: @woodman $ORIC $PFE Great summary. That PFE buy gives me a lot of confidence in Oric's prospects. Patience here will probably be rewarded. My position is about 5% filled and just slowly adding on pullbacks. Like today!
  • woodman: @steve71 $ORIC $PFE - Thanks. Makes sense. My position is more advanced, which may or may not be a good thing.... :-?
  • Bs7518: @woodman $ORIC $PFE Thanks for the update is this add territory ?
  • woodman: $ORIC giving an add opportunity.
  • sierramp: @woodman $ORIC I added. Looks like the handle to the Feb-Apr Cup.
  • woodman: $ORIC (targeting multiple solid tumor cancers) and $ETNB (another one in NASH) remain strong.
  • woodman: $ORIC testing 6.00 resistance. If it can get past that, there's a 6.30 speed bump en route to 6.85.
  • sierramp: $ORIC has a nice C&H formation Feb-Apr with handle or base forming now. This is a low vol stock however the kicker with this biotech that is currently in Ph 1b trials for prostate cancer, multiple myeloma and solid tumors/advanced malignancies is the sale of an offered 5.38M shares sold directly to Pfizer at $4.65 a share <- per @Woodman who is the biotech guru. Interestingly, this stock is currently 14.32% short with 18.4 days to cover. I had a Buy Limit in this morning. My price was hit but the order didn't execute, nobody wanting to sell apparently. Against my internal advice, I pulled the trigger anyway. So far I'm not regretting that move.
  • woodman: $ORIC - I added this morning. Getting a decent bounce off the 8dEMA. A bounce off the old breakout level ~4.30, or the lower 20d or 21dEMA even better - would have been safer, but this is working so far.
  • woodman: @woodman $ORIC - [CORRECTION] - I meant breakout level of ~5.30, not 4.30. Bad typing. I know hope isn't a strategy, but I do hope some day we will have a functioning edit button again.
  • Bs7518: @woodman $ORIC Thank you I followed and added this Am
  • sierramp: @woodman $ORIC Agree re: edit. I thought we'd see a bit more of a cup before the handle formation but I'll take this.
  • woodman: $ORIC strength continues.
  • stairm01: @woodman $ORIC Thanks Woodman! I entered last Thursday when you pointed this one out. Long stock with stop at break even now.
  • woodman: @stairm01 $ORIC - Good luck and welcome aboard. (I'm in just a little ahead of you with my first buys on 3/16 and 3/17, then added on Thursday). We've got some time before its Phase 1b data readouts (discussed in my prior posts). I thought maybe we'd get a pullback today to test the breakout but not so far. We'll see....
  • debeers: @woodman $ORIC nice one
  • woodman: $ORIC cancer biotech I mentioned before is breaking out. Fwiw, price targets from four outfits are: 14 (Oppy), 15 (Guggenheim & JPM) and 16 (HCW).
  • mharps: $ORIC nice pop wish I had more
  • Justhanging48: @mharps $ORIC Pretty much under the radar, unless you followed Thomson Reuters, they have had a price target of $13 for the past 90 days.
Visit the Trading Forum to join in the discussion.
Stock Price $9.08
Change 8.10%
Volume 2,138,850

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.

Request Video of ORIC
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!